PT3436591T - Veículos de entrega derivados da proteína do revestimento adenoviral - Google Patents

Veículos de entrega derivados da proteína do revestimento adenoviral

Info

Publication number
PT3436591T
PT3436591T PT177154440T PT17715444T PT3436591T PT 3436591 T PT3436591 T PT 3436591T PT 177154440 T PT177154440 T PT 177154440T PT 17715444 T PT17715444 T PT 17715444T PT 3436591 T PT3436591 T PT 3436591T
Authority
PT
Portugal
Prior art keywords
coat protein
delivery vehicles
protein derived
adenoviral coat
derived delivery
Prior art date
Application number
PT177154440T
Other languages
English (en)
Original Assignee
The European Molecular Biology Laboratory
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The European Molecular Biology Laboratory, Centre Nat Rech Scient filed Critical The European Molecular Biology Laboratory
Publication of PT3436591T publication Critical patent/PT3436591T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT177154440T 2016-03-31 2017-03-31 Veículos de entrega derivados da proteína do revestimento adenoviral PT3436591T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16163372 2016-03-31

Publications (1)

Publication Number Publication Date
PT3436591T true PT3436591T (pt) 2023-04-11

Family

ID=55650297

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177154440T PT3436591T (pt) 2016-03-31 2017-03-31 Veículos de entrega derivados da proteína do revestimento adenoviral

Country Status (16)

Country Link
US (2) US11274127B2 (pt)
EP (2) EP3436591B1 (pt)
JP (3) JP7466271B2 (pt)
CN (2) CN109415739A (pt)
CA (1) CA3018427A1 (pt)
DK (1) DK3436591T3 (pt)
ES (1) ES2941339T3 (pt)
FI (1) FI3436591T3 (pt)
HR (1) HRP20230197T1 (pt)
HU (1) HUE061690T2 (pt)
LT (1) LT3436591T (pt)
PL (1) PL3436591T3 (pt)
PT (1) PT3436591T (pt)
RS (1) RS64059B1 (pt)
SI (1) SI3436591T1 (pt)
WO (1) WO2017167988A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043081A1 (en) 2017-08-29 2019-03-07 Ruprecht-Karls-Universität Heidelberg RATIONALLY DESIGNED PSEUDOVIRAL PARTICLES FOR THE MODULATION OF CHIMERIC ANTIGENIC RECEPTOR (CAR) T CELL THERAPY
JP2021532836A (ja) * 2018-07-31 2021-12-02 イモフォロン リミテッド アデノウイルス ペントンベースのゼリーロールフォールドドメイン由来である多量体化ポリペプチド
JP2023513512A (ja) 2020-02-05 2023-03-31 イモフォロン リミテッド アデノウイルス ペントンベースの可変ドメイン由来の操作されたポリペプチド
WO2022121917A1 (zh) * 2020-12-11 2022-06-16 康希诺生物股份公司 一种药物组合物及其应用
WO2022218997A1 (en) 2021-04-12 2022-10-20 Centre National De La Recherche Scientifique (Cnrs) Novel universal vaccine presenting system
CN114805599B (zh) * 2022-03-29 2023-08-04 华南农业大学 一种基于ADDomer嵌合猪O型口蹄疫病毒抗原表位的VLPs及应用
WO2024042100A1 (en) 2022-08-22 2024-02-29 Imophoron Limited Adenovirus penton-based virus-like particles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
WO1997018317A1 (fr) * 1995-11-13 1997-05-22 Commissariat A L'energie Atomique Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
WO1997020575A1 (en) * 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Targeted adenovirus vectors
AU2001265154A1 (en) * 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
WO2005075506A1 (en) * 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
AU2010209938A1 (en) 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
PL222496B1 (pl) * 2009-04-10 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną
PL222497B1 (pl) * 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
WO2012150478A1 (en) * 2010-04-28 2012-11-08 Institut Gustave Roussy Adenovirus vaccine vectors
EP2809788B1 (en) * 2012-02-02 2019-09-04 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
US10376549B2 (en) * 2015-01-20 2019-08-13 Adcure Biotechnologies, Llc. Detargeted adenovirus variants and related methods
BR112017023171A2 (pt) * 2015-04-30 2018-07-17 Psioxus Therapeutics Limited adenovírus oncolítico que codifica proteína b7
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
PL3436591T3 (pl) 2023-06-26
WO2017167988A1 (en) 2017-10-05
CN109415739A (zh) 2019-03-01
HUE061690T2 (hu) 2023-08-28
EP3436591B1 (en) 2023-01-04
HRP20230197T1 (hr) 2023-03-31
CN117534735A (zh) 2024-02-09
CA3018427A1 (en) 2017-10-05
DK3436591T3 (da) 2023-03-20
JP2022166109A (ja) 2022-11-01
EP4190906A1 (en) 2023-06-07
JP2019512261A (ja) 2019-05-16
SI3436591T1 (sl) 2023-05-31
JP2022166110A (ja) 2022-11-01
JP7466271B2 (ja) 2024-04-12
US20200325179A1 (en) 2020-10-15
RS64059B1 (sr) 2023-04-28
LT3436591T (lt) 2023-04-11
ES2941339T3 (es) 2023-05-22
US20220162267A1 (en) 2022-05-26
FI3436591T3 (fi) 2023-03-30
US11274127B2 (en) 2022-03-15
EP3436591A1 (en) 2019-02-06

Similar Documents

Publication Publication Date Title
IL289250A (en) Stabilized antimicrobial peptides
EP3287400A4 (en) Delivery system
GB201909833D0 (en) Temperature-controlled delivery vehicle
EP3287399A4 (en) Delivery system
EP3347035A4 (en) CARTON PEPTIDES
EP3325633A4 (en) RECOMBINANT VECTORS COMPRISING A 2A PEPTIDE
LT3436591T (lt) Pristatymo transporteriai, kilę iš adenoviruso apvalkalo baltymo
EP3435978A4 (en) RELEASE SYSTEM
EP3194422A4 (en) Anti-microbial peptides
HK1249034A1 (zh) 遞送媒介物
HK1247831A1 (zh) 蛋白質或肽傳遞用的可溶性微針
EP3223802A4 (en) Stealth nanocapsules for protein delivery
IL263773A (en) Protein for conduction to the brain
GB2555125B (en) Coating system
EP3463414C0 (en) PROTEIN INTERFACES
GB201603517D0 (en) Improved goods delivery system
GB201607534D0 (en) Peptides
EP3266794A4 (en) Peptide
EP3380115B8 (en) Peptides from piwil1
GB201604468D0 (en) Peptides
EP3389641A4 (en) PROTEIN NANOCAPSULES WITH REMOVABLE ZWITTERIONIC COATING FOR PROTEIN DELIVERY
GB2558968B (en) G Proteins
EP3424943A4 (en) Peptide
EP3253777A4 (en) Rvg derived peptides
EP3464377A4 (en) PEPTIDES GIVEN FROM DSG2